SCHEMBL6510380

SCHEMBL6510380

Cn1cc(NC(=O)OC(C)(C)C)cc1-c1nc2ccc(C(=O)O)nc2[nH]1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACSS2 Q9NR19 1/20 0.37
RAB9A P51151 1/20 0.36
MAPT P10636 3/20 0.36
MAPK1 P28482 1/20 0.36
MAP4K4 O95819 1/20 0.35
LCK P06239 1/20 0.34
EGFR P00533 1/20 0.34
EGLN2 Q96KS0 1/20 0.34
GSK3B P49841 1/20 0.33
DYRK1A Q13627 1/20 0.33
TOP2A P11388 1/20 0.33
TOP2B Q02880 1/20 0.33
TP53 P04637 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPK14 Q16539 1/20 0.33
BRD4 O60885 1/20 0.33
SCD O00767 1/20 0.33
CNR2 P34972 1/20 0.32
AURKA O14965 1/20 0.32
AURKB Q96GD4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6511101 0.91 RAB9A (0.35) ACSS2RAB9AMAPTMAPK1MAP4K4
SCHEMBL14879048 0.83 LCK (0.46) RAB9AMAPTMAPK1LCKEGFR
SCHEMBL15233336 0.82 ACSS2 (0.35) ACSS2RAB9AMAPTMAPK1MAP4K4
SCHEMBL15233051 0.82 ACSS2 (0.35) ACSS2RAB9AMAPTMAPK1MAP4K4
SCHEMBL5560010 0.81 MAPT (0.39) ACSS2RAB9AMAPTMAPK1LCK
SCHEMBL6515389 0.80 ACSS2 (0.35) ACSS2RAB9AMAPTMAPK1MAP4K4
SCHEMBL14879027 0.79 RAB9A (0.38) RAB9AMAPTMAPK1EGFRSMN1; SMN2
SCHEMBL15233045 0.78 KDM4E (0.47) RAB9AMAPTMAPK1LCKEGFR
SCHEMBL6513671 0.77 ATR (0.36) ACSS2RAB9AMAPTMAPK1MAP4K4
SCHEMBL5561204 0.77 RHEB (0.41) RAB9AMAPTMAPK1LCKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524899-B2 Oligopeptide containing fused 6-membered ring forming complexes with double stranded dna; complexes can be used for identification of specific dsDNA sequences, inhibiting gene transcription, therapeutic for inhibiting proliferation of undesired cells or modulation of expression of specific gene CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2013-09-03 US disclosed
US-8524899-B2 Oligopeptide containing fused 6-membered ring forming complexes with double stranded dna; complexes can be used for identification of specific dsDNA sequences, inhibiting gene transcription, therapeutic for inhibiting proliferation of undesired cells or modulation of expression of specific gene CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2013-09-03 US disclosed
US-8524899-B2 Oligopeptide containing fused 6-membered ring forming complexes with double stranded dna; complexes can be used for identification of specific dsDNA sequences, inhibiting gene transcription, therapeutic for inhibiting proliferation of undesired cells or modulation of expression of specific gene CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2013-09-03 US disclosed
EP-1599474-B1 Heterocyclic oligomeric compounds for DNA recognition CALIFORNIA INST OF TECHN (US) 2013-04-24 EP disclosed
US-20050026174-A1 Alternative heterocycles for DNA recognition CALIFORNIA INSTITUTE OF TECHNOLOGY 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026174-A1 Alternative heterocycles for DNA recognition DDB1, PCNA, DNA2 ACSS2 2587/4885RAB9A 4515/4885MAPT 4324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.